1
|
Marascio N, Pavia G, Romeo I, Talarico C, Di Salvo S, Reale M, Marano V, Barreca GS, Fabiani F, Perrotti N, De Siena M, Giancotti F, Gravina T, Alcaro S, Artese A, Torti C, Liberto MC, Focà A. Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling. J Med Virol 2018; 90:1257-1263. [PMID: 29575060 DOI: 10.1002/jmv.25073] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2017] [Accepted: 03/06/2018] [Indexed: 12/12/2022]
Abstract
We report a real-life 3D therapy failure in a patient treated with ombitasvir (OMV)/paritaprevir/ritonavir and dasabuvir without ribavirin (3D-R). He had therapy failure at week 12 after the end of treatment. We detected resistance-associated substitutions (RASs) plus polymorphisms on NS3, NS5A, and NS5B target regions by population sequencing (15% cut-off) at baseline, at relapse and during follow-up. About this, NS5A RASs generally persist longer than resistances in the other target genes and may impact treatment outcome. Therefore, to evaluate OMV drug-resistance mechanism, we studied the acquired RAS plus polymorphisms on NS5A phosphoprotein by computational studies. OMV showed a higher affinity towards baseline and 93H/108 K mutant structure (follow-up) with respect to 93H/R108 mutant structure (relapse) on phosphoprotein. By Molecular Dynamics simulations (MDs), structural information about the protein stability in presence of OMV were observed. According to our data, molecular modeling approach has proved to be a powerful method to evaluate the impact of these RASs plus specific amino acid (AA) changes on phosphoprotein.
Collapse
Affiliation(s)
- Nadia Marascio
- Department of Health Sciences, Unit of Clinical Microbiology, School of Medicine, University of "Magna Graecia", Catanzaro, Italy
| | - Grazia Pavia
- Department of Health Sciences, Unit of Clinical Microbiology, School of Medicine, University of "Magna Graecia", Catanzaro, Italy
| | - Isabella Romeo
- Department of Health Sciences, University of "Magna Graecia", Catanzaro, Italy
| | - Carmine Talarico
- Department of Health Sciences, University of "Magna Graecia", Catanzaro, Italy
| | | | - Mariaconcetta Reale
- Department of Health Sciences, Unit of Clinical Microbiology, School of Medicine, University of "Magna Graecia", Catanzaro, Italy
| | - Vito Marano
- Department of Health Sciences, Unit of Clinical Microbiology, School of Medicine, University of "Magna Graecia", Catanzaro, Italy
| | - Giorgio Settimo Barreca
- Department of Health Sciences, Unit of Clinical Microbiology, School of Medicine, University of "Magna Graecia", Catanzaro, Italy
| | - Fernanda Fabiani
- Unit of Medical Genetics, "Mater Domini" University Hospital, Catanzaro, Italy
| | - Nicola Perrotti
- Unit of Medical Genetics, "Mater Domini" University Hospital, Catanzaro, Italy
| | - Massimo De Siena
- Unit of Hepatology, "Mater Domini" University Hospital, Catanzaro, Italy
| | | | - Tiziana Gravina
- Unit of Hepatology, "Mater Domini" University Hospital, Catanzaro, Italy
| | - Stefano Alcaro
- Department of Health Sciences, University of "Magna Graecia", Catanzaro, Italy
| | - Anna Artese
- Department of Health Sciences, University of "Magna Graecia", Catanzaro, Italy
| | - Carlo Torti
- Department of Medical and Surgical Sciences, Unit of Infectious and Tropical Diseases, School of Medicine, University of "Magna Graecia", Catanzaro, Italy
| | - Maria Carla Liberto
- Department of Health Sciences, Unit of Clinical Microbiology, School of Medicine, University of "Magna Graecia", Catanzaro, Italy
| | - Alfredo Focà
- Department of Health Sciences, Unit of Clinical Microbiology, School of Medicine, University of "Magna Graecia", Catanzaro, Italy
| |
Collapse
|